For citations:
Gusev D.A., Rudakova A.V., Uskov A.N., Konovalova L.N., Lobzin Yu.V. Cost-effectiveness of narlaprevir in the chronic hepatitis C (genotype 1) therapy in treatment-naïve patients and relapsers. Journal Infectology. 2016;8(3):122-125. (In Russ.)